These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 1821262)

  • 1. A retrospective analysis of the effects of anticholinergic medication on memory performance in Parkinson's disease.
    Levin BE; Llabre MM; Reisman S; Weiner WJ; Brown MC
    J Neuropsychiatry Clin Neurosci; 1991; 3(4):412-6. PubMed ID: 1821262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic dementia in Parkinson's disease treated by anticholinergic agents. Neuropsychological and neuroradiological examination.
    Nishiyama K; Mizuno T; Sakuta M; Kurisaki H
    Adv Neurol; 1993; 60():479-83. PubMed ID: 8420174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parkinson's disease in the elderly: current management strategies.
    Aminoff MJ
    Geriatrics; 1987 Jul; 42(7):31-7. PubMed ID: 3110015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Chronic dementia in Parkinson disease treated by long-term administration of anticholinergic drug--evaluation of neuropsychological test, PET, and SPECT].
    Nishiyama K; Mizuno T; Sakuta M; Kurisaki H; Momose T
    Rinsho Shinkeigaku; 1991 Jun; 31(6):625-31. PubMed ID: 1934777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of selegiline on cognitive functions in Parkinson's disease.
    Dixit SN; Behari M; Ahuja GK
    J Assoc Physicians India; 1999 Aug; 47(8):784-6. PubMed ID: 10778622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levodopa improves time-based prospective memory in Parkinson's disease.
    Costa A; Peppe A; Brusa L; Caltagirone C; Gatto I; Carlesimo GA
    J Int Neuropsychol Soc; 2008 Jul; 14(4):601-10. PubMed ID: 18577289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive dysfunction in early onset parkinsonism.
    Tsai CH; Lu CS; Hua MS; Lo WL; Lo SK
    Acta Neurol Scand; 1994 Jan; 89(1):9-14. PubMed ID: 8178636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of clinical motor variables and medication dosage on working memory in Parkinson's disease.
    Moustafa AA; Bell P; Eissa AM; Hewedi DH
    Brain Cogn; 2013 Jul; 82(2):137-45. PubMed ID: 23660434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term memory in Parkinson's disease after withdrawal of long-term anticholinergic therapy.
    van Herwaarden G; Berger HJ; Horstink MW
    Clin Neuropharmacol; 1993 Oct; 16(5):438-43. PubMed ID: 8221704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parkinson's disease duration determines effect of dopaminergic therapy on ventral striatum function.
    MacDonald AA; Monchi O; Seergobin KN; Ganjavi H; Tamjeedi R; MacDonald PA
    Mov Disord; 2013 Feb; 28(2):153-60. PubMed ID: 23165957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The source of the memory impairment in Parkinson's disease: acquisition versus retrieval.
    Chiaravalloti ND; Ibarretxe-Bilbao N; DeLuca J; Rusu O; Pena J; García-Gorostiaga I; Ojeda N
    Mov Disord; 2014 May; 29(6):765-71. PubMed ID: 24615718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Working memory functioning in medicated Parkinson's disease patients and the effect of withdrawal of dopaminergic medication.
    Fournet N; Moreaud O; Roulin JL; Naegele B; Pellat J
    Neuropsychology; 2000 Apr; 14(2):247-53. PubMed ID: 10791864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Memory changes in Parkinson's disease. Relation with clinical variables].
    Bruna O; Junqué C; Vendrell P; Roig C; Grau-Veciana JM
    Neurologia; 1992 Feb; 7(2):55-60. PubMed ID: 1610601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Confusion, dementia and anticholinergics in Parkinson's disease.
    de Smet Y; Ruberg M; Serdaru M; Dubois B; Lhermitte F; Agid Y
    J Neurol Neurosurg Psychiatry; 1982 Dec; 45(12):1161-4. PubMed ID: 7161613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-lasting drug holiday in Parkinson's disease.
    Bermejo F; Calandre L; Molina JA; Martinez P; De Yebenes JG
    Adv Neurol; 1987; 45():503-6. PubMed ID: 3103392
    [No Abstract]   [Full Text] [Related]  

  • 16. The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia.
    Reddy S; Factor SA; Molho ES; Feustel PJ
    Mov Disord; 2002 Jul; 17(4):676-81. PubMed ID: 12210856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopaminergic effects on cognitive performance in patients with Parkinson's disease.
    Lange KW; Paul GM; Naumann M; Gsell W
    J Neural Transm Suppl; 1995; 46():423-32. PubMed ID: 8821078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Memory deficits and anticholinergic levels in chronic schizophrenia.
    Perlick D; Stastny P; Katz I; Mayer M; Mattis S
    Am J Psychiatry; 1986 Feb; 143(2):230-2. PubMed ID: 3946662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology of hallucinations induced by long-term drug therapy.
    Goetz CG; Tanner CM; Klawans HL
    Am J Psychiatry; 1982 Apr; 139(4):494-7. PubMed ID: 6802003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopaminergic influence on disturbed spatial discrimination in Parkinson's disease.
    Shin HW; Kang SY; Sohn YH
    Mov Disord; 2005 Dec; 20(12):1640-3. PubMed ID: 16092109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.